Huadong enters licence deal for MC2 TherapeuticsMC2 Therapeutics’ Wynzora cream

01 Sep 2023
www.pharmaceutical-technology.com
License out/in
Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream
Preview
Source: Pharmaceutical Technology
The cream is intended for topical treatment of plaque psoriasis, including scalp psoriasis. Credit: estkallee / Shutterstock.com
Hangzhou Zhongmei Huadong Pharmaceutical (Huadong) has entered an agreement to acquire exclusive licence rights for the development and marketing of MC2 Therapeutics’ Wynzora cream in Greater China.
Wynzora is a topical treatment for adults with plaque psoriasis, including scalp psoriasis.
Recommended Reports
Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Ketamine + Midazolam) in Sedation GlobalData
Huadong enters licence deal for MC2 Therapeutics’ Wynzora cream
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (aspirin + ketamine) GlobalData
View allCompanies IntelligenceMC2Hangzhou Zhongmei Huadong Pharmaceutical Co LtdMC2 Therapeutics ASView all
The licence rights are for regions comprising mainland China, Hong Kong, Macau and Taiwan.
Huadong will make upfront and regulatory milestone payments totalling $16m to MC2, which is entitled to receive a further $36m on meeting sales-based milestones.
MC2 will also receive tiered royalty payments from Huadong.
Huadong will handle Wynzora’s development and marketing in Greater China while a joint steering committee with representatives from both firms will oversee these activities.
The cream-based drug comprises a fixed-dose combination of calcipotriene and betamethasone dipropionate, and has received approvals in the US and Europe.
MC2 Therapeutics CEO Jesper Lange stated: “As a leading pharmaceutical company in Asia with a clear ambition and strategy to grow its franchise in the treatment of immune-mediated skin diseases, Huadong is an excellent partner to leverage Wynzora in Greater China.
“This deal substantiates our strategy to make Wynzora available to as many people as possible globally, as we continue to develop and expand our pipeline of innovative first-in-class treatments for immune-mediated inflammatory conditions.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.